05/08/2026 | Press release | Distributed by Public on 05/08/2026 14:34
|
Delaware
|
22-0790350
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
Large Accelerated Filer
|
☒
|
Accelerated Filer
|
☐
|
|||
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
☐
|
|||
|
Emerging growth company
|
☐
|
|||||
| Item 3. |
Incorporation of Documents by Reference.
|
|
|
(a) |
The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 11, 2026 (the "Annual Report"), including the information specifically incorporated by reference therein from the Company's Definitive Proxy Statement on Schedule 14A, filed with the Commission on March 25, 2026.
|
|
|
(b) |
The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Commission on April 30, 2026.
|
|
|
(c) |
The Registrant's Current Report on Form 8-K filed on May 8, 2026; and
|
|
|
(d) |
The description of the Registrant's Common Stock contained under the caption "Description of Capital Stock - Bristol Myers Squibb Common Stock" in the "Description of Bristol-Myers Squibb Company's securities registered pursuant to Section 12 of the Securities Exchange Act of 1934", filed as Exhibit 4a to the Annual Report, and all amendments or reports filed for the purpose of updating such description.
|
| Item 4. |
Description of Securities.
|
| Item 5. |
Interests of Named Experts and Counsel
|
| Item 6. |
Indemnification of Directors and Officers.
|
| Item 7. |
Exemption from Registration Claimed.
|
| Item 8. |
Exhibits.
|
|
Exhibit
Number
|
Description
|
|
|
Amended and Restated Certificate of Incorporation of Bristol-Myers Squibb Company, as further amended (incorporated herein by reference to Exhibit 3a to Bristol-Myers-Squibb Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024).
|
||
|
Bylaws of Bristol-Myers Squibb Company, as amended as of May 4, 2021 (incorporated herein by reference to Exhibit 3b to Bristol-Myers Squibb Company's Current Report on Form 8-K filed on May 4, 2021).
|
||
|
5.1*
|
Opinion of Hogan Lovells US LLP regarding the legality of the Common Stock registered hereby.
|
|
|
Bristol-Myers Squibb Company 2026 Stock Award and Incentive Plan (incorporated herein by reference to Exhibit B to Bristol-Myers Squibb Company's Definitive Proxy Statement filed on March 25, 2026).
|
||
|
23.1*
|
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
|
|
|
23.2*
|
Consent of Hogan Lovells US LLP (included in Exhibit 5.1).
|
|
|
24.1*
|
Powers of Attorney (included in the signature pages hereof).
|
|
|
107*
|
Filing Fee Table.
|
|
*
|
Filed herewith
|
| Item 9. |
Undertakings.
|
|
(a)
|
The undersigned Registrant hereby undertakes:
|
|
BRISTOL-MYERS SQUIBB COMPANY
|
||
|
By:
|
/s/ Cari Gallman
|
|
|
Cari Gallman
|
||
|
Executive Vice President, General Counsel and Chief Policy Officer
|
||
|
SIGNATURE
|
TITLE
|
DATE
|
||
|
/s/ Christopher Boerner, Ph.D.
|
Chairman of the Board and Chief Executive Officer (Principal Executive Officer)
|
May 8, 2026
|
||
|
Christopher Boerner, Ph.D.
|
||||
|
/s/ David V. Elkins
|
Executive Vice President and Chief Financial Officer (Principal Financial Officer)
|
May 8, 2026
|
||
|
David V. Elkins
|
||||
|
/s/ Phil M. Holzer
|
Senior Vice President and Corporate Controller (Principal Accounting Officer)
|
May 8, 2026
|
||
|
Phil M. Holzer
|
||||
|
/s/ Peter J. Arduini
|
Director
|
May 8, 2026
|
||
|
Peter J. Arduini
|
||||
|
/s/ Deepak L. Bhatt, M.D. MPH MBA
|
Director
|
May 8, 2026
|
||
|
Deepak L. Bhatt, M.D. MPH MBA
|
||||
|
/s/ Julia A. Haller, M.D.
|
Director
|
May 8, 2026
|
||
|
Julia A. Haller, M.D.
|
||||
|
/s/ Manuel Hidalgo Medina, M.D., Ph.D.
|
Director
|
May 8, 2026
|
||
|
Manuel Hidalgo Medina, M.D., Ph.D.
|
||||
|
/s/ Michael R. McMullen
|
Director
|
May 8, 2026
|
||
|
Michael R. McMullen
|
||||
|
/s/ Paula A. Price
|
Director
|
May 8, 2026
|
||
|
Paula A. Price
|
||||
|
/s/ Derica W. Rice
|
Director
|
May 8, 2026
|
||
|
Derica W. Rice
|
||||
|
/s Theodore R. Samuels
|
Director
|
May 8, 2026
|
||
|
Theodore R. Samuels
|
||||
|
/s/ Karen H. Vousden, Ph.D.
|
Director
|
May 8, 2026
|
||
|
Karen H. Vousden, Ph.D.
|
||||
|
/s/ Phyllis R. Yale
|
Director
|
May 8, 2026
|
||
|
Phyllis R. Yale
|
||||